Concentra Raises FY 2026 Guidance on Strong Q2 Performance
Event summary
- Concentra reported Q2 2026 revenue growth of 10.0% to $606.0 million, with net income up 45.7% YoY.
- Adjusted EBITDA grew 22.5% YoY to $140.9 million, while free cash flow surged 91.6% to $121.0 million.
- Matt DiCanio will become CEO on November 1, 2026, replacing Keith Newton who transitions to executive chairman.
- Concentra raised FY 2026 guidance, targeting revenue of $2.325B–$2.375B and Adjusted EBITDA of $485M–$495M.
The big picture
Concentra’s strong Q2 performance and raised guidance reflect its leadership in occupational health services, driven by operational efficiency and strategic acquisitions. The leadership transition underscores a focus on continuity as the company approaches its 50th year, navigating industry shifts toward value-based care and employer-focused health solutions.
What we're watching
- Leadership Transition Impact
- How Matt DiCanio’s CEO tenure will affect Concentra’s growth strategy and operational execution.
- Revenue Diversification
- Whether Concentra can sustain its revenue per visit growth amid changing occupational health dynamics.
- Financial Discipline
- The pace at which Concentra reduces its net leverage ratio below 3.0x while maintaining capital expenditures.